Royal Bank of Canada raised its price target for Apogee Therapeutics on July 10, 2026, with Mizuho Securities also updating its ratings.
1 report, 1 independent
Updated Jul 10
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Royal Bank of Canada raised its price target for Apogee Therapeutics on July 10, 2026, with Mizuho Securities also updating its ratings.
Who's involved
What this event is mainly aboutKeep exploring
The entities involved
-
Royal Bank of Canada
financial institution in Canada
-
Mizuho Securities
Japanese investment banking company
Related events
- Mizuho Securities raised its price target for Highwoods Properties (HIW) on July 23, 2026.
- Royal Bank of Canada adjusted its rating on Ball Corporation stock, while Mizuho Securities set a price objective, coinciding with Ball's SEC filings.
- Royal Bank of Canada upped its target price for Citizens Financial Group.
- Mizuho Securities raised its price target on Dell Technologies.
- Royal Bank of Canada issued a price objective and Benzinga reported a target price reduction for Aardvark Therapeutics, Inc.